Will CORT revise FY2026 revenue guidance below $900M by Q2 2026 earnings?

The FY26 guidance of $900M-$1B was issued 2026-02-24, AFTER the Cushing's CRL (12/30) and AFTER the Q4 2025 pharmacy disruption. The guidance therefore already incorporates the known negative events. A cut below $900M would require NEW information: (a) Q1 2026 revenue materially below ~$200-210M pace, OR (b) AG compression accelerating beyond modeled, OR (c) Teva-related ANDA filings accelerating share erosion. The guide-cut base rate for companies that cut 3x in prior cycle is historically ~35-45% for a 4th cut within first two quarters, but management has $532M cash cushion removing defensive pressure to cut, and Lifyorli approval provides a ~$20-50M Year 1 upside offset. Strong anchor effect: management avoids 4th cut when possible to preserve narrative. Net: 0.35.

The base rate is not just about cut probability but about cut-below-$900M specifically. The $900M low end is ~18% YoY growth, which is meaningful for a company facing: (1) Korlym scripts-tablets gap uncertainty in Q1, (2) AG volume share at 78% compressing per-patient revenue, (3) Teva Fed Cir loss creating forward uncertainty, (4) Lifyorli contribution characterized as 'small portion'. If Q1 2026 comes in at $190M (2.5% below Q4 $202M but meaningful miss vs pace required for $900M), management faces a decision. Management cut in mid-2025 when Q2 disappointed; same pattern would suggest ~40-50% cut probability in first two quarters. Myth Meter GAP_BULLISH reading reinforces the tendency to over-promise, which makes subsequent cut MORE likely. Net: 0.42.

Important asymmetry: narrowing the range (e.g., $900M-$950M instead of $900M-$1B) or holding at low-end $900M does NOT resolve YES. Only revision below $900M low end does. This is a high bar that requires management to explicitly signal worse-than-expected trajectory, which CEO Belanoff and CFO Maduck both indicated confidence about at Q4 2025 earnings. The narrative-discipline argument is strong: a 4th guide cut within 6 months of issuing would be highly punishing to management credibility. More likely scenarios: (a) management reaffirms $900M-$1B through Q2 even with a weak Q1, betting on H2 ramp, OR (b) narrow the range without breaking the $900M floor. The guide-cut-below-floor probability is ~30%.

Q4 2025 revenue ~$202M. To hit $900M FY26 floor requires ~$225M per quarter average - i.e., growth each quarter through year-end. Q1 is typically seasonally softer, and pharmacy transition disruption may carry into Q1. If Q1 comes in at $200-215M, management has incentive to reaffirm with H2 ramp story; only at $180-195M would they cut. Probability of Q1 at $180-195M is maybe 30-40%. Conditional on Q1 weakness, probability of Q2 cut is ~60-70%. Joint: ~25-30%. Plus scenario where Q1 meets but Q2 weakness triggers: +5-10% probability. Net: 0.35.

Management's 'never been more confident' rhetoric during three consecutive prior guide cuts suggests they issue confident guidance and then cut when reality doesn't cooperate. The same pattern would produce Q2 cut at roughly 35-40% base rate. Critical: FY26 guide was issued after the negative events, so it incorporates known negatives more than prior guides. But: Q4 2025 pharmacy disruption was described as resolved - if Q1 proves it wasn't, the reset would be material. Net: 0.38.

I weight management narrative discipline highly. A 4th consecutive guide cut would be brand-damaging, and management issued the $900M-$1B range AFTER both the Cushing's CRL and Q4 pharmacy disruption - they ALREADY absorbed those negatives into the range. The negative scenarios requiring a cut are: (a) Q1 2026 pharmacy disruption was structural not transitory, (b) material new information in H1 (e.g., AG shift beyond modeling, Teva ANDA filing). Both are possible but not highly probable in the 4-month Q1-Q2 window. Settle at 0.32.

Three prior guide cuts establish pattern. FY26 guide already incorporates known negatives. Q1 pace required for $900M floor is ~$225M (vs $202M Q4). Cut probability in first two quarters: 30-40%. Net 0.35.

Myth Meter GAP_BULLISH signal on management rhetoric argues management over-promises. Three prior cuts support. But FY26 guide post-CRL is realistic floor. Settle above 1/3 and below 1/2 at 0.40.

4th consecutive guide cut within 6 months is rare (brand damage, narrative control). Most likely scenario is reaffirmation through Q1 earnings and cut-or-reaffirm at Q2. Cut in Q1 requires acute negative signal; probability lower. Net 0.32.